HRP20030822B1 - 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands - Google Patents

4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Info

Publication number: HRP20030822B1
Authority: HR; Croatia
Prior art keywords: pyrazolo; pharmaceutically acceptable; methoxypyrid; butylamino; triazine
Prior art date: 2001-03-13

Application number

HR20030822A

Other languages

English (en)

Croatian (hr)

Inventor

J. Gilligan Paul

Original Assignee

Bristol-Myers Squibb Pharma Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-13

Filing date

2002-03-06

Publication date

2008-01-31

2002-03-06 Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company

2004-04-30 Publication of HRP20030822A2 publication Critical patent/HRP20030822A2/xx

2008-01-31 Publication of HRP20030822B1 publication Critical patent/HRP20030822B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Addiction (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Virology (AREA)
Cardiology (AREA)
Oncology (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)

HR20030822A 2001-03-13 2002-03-06 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands HRP20030822B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27540301P	2001-03-13	2001-03-13
PCT/US2002/006837 WO2002072202A1 (en)	2001-03-13	2002-03-06	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Publications (2)

Publication Number	Publication Date
HRP20030822A2 HRP20030822A2 (en)	2004-04-30
HRP20030822B1 true HRP20030822B1 (en)	2008-01-31

Family

ID=23052141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030822A HRP20030822B1 (en)	2001-03-13	2002-03-06	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Country Status (35)

Country	Link
US (4)	US20030125330A1 (es)
EP (1)	EP1368094B1 (es)
JP (1)	JP4549630B2 (es)
KR (1)	KR100875595B1 (es)
CN (1)	CN100427093C (es)
AR (1)	AR032986A1 (es)
AT (1)	ATE355102T1 (es)
AU (1)	AU2002245605B2 (es)
BG (1)	BG66331B1 (es)
BR (1)	BR0208357A (es)
CA (1)	CA2440553C (es)
CY (1)	CY1106607T1 (es)
CZ (1)	CZ20032481A3 (es)
DE (1)	DE60218434T2 (es)
DK (1)	DK1368094T3 (es)
EE (1)	EE05433B1 (es)
ES (1)	ES2282401T3 (es)
GE (1)	GEP20053608B (es)
HR (1)	HRP20030822B1 (es)
HU (1)	HU229317B1 (es)
IL (2)	IL157615A0 (es)
IS (1)	IS2839B (es)
MX (1)	MXPA03008185A (es)
MY (1)	MY146935A (es)
NO (1)	NO328580B1 (es)
NZ (1)	NZ528207A (es)
PL (1)	PL208278B1 (es)
PT (1)	PT1368094E (es)
RS (1)	RS50863B (es)
RU (1)	RU2292347C2 (es)
SK (1)	SK287603B6 (es)
TW (1)	TWI257388B (es)
UA (1)	UA74634C2 (es)
WO (1)	WO2002072202A1 (es)
ZA (1)	ZA200306995B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094782B1 (en) *	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
CA2440553C (en) *	2001-03-13	2010-06-08	Paul J. Gilligan	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
FR2842809A1 (fr) *	2002-07-26	2004-01-30	Greenpharma Sas	NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
AR041470A1 (es) *	2002-10-17	2005-05-18	Upjohn Co	Compuestos de pirrolo (1,2 - b) piridazina y sus usos
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) *	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7041671B2 (en) *	2003-04-02	2006-05-09	Pfizer Inc	Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en) *	2003-04-04	2006-04-25	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en)	2003-04-04	2006-06-06	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
WO2004092176A1 (en) *	2003-04-15	2004-10-28	Pharmacia & Upjohn Company Llc	Pyrrolo[1,2-b]pyridazine compounds and their uses
US7153961B2 (en)	2003-11-25	2006-12-26	Bristol-Myers Squibb Pharma Co.	Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7208596B2 (en) *	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
SI2094709T1 (sl)	2006-09-20	2011-01-31	Lilly Co Eli	Tiazol pirazolopirimidini kot antagonisti crf1 receptorja
HK1207304A1 (en) *	2012-04-23	2016-01-29	Hmnc Value Gmbh	Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en)	2012-06-15	2012-08-01	Holsboermaschmeyer Neurochemie Gmbh	V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
HK1215170A1 (zh)	2012-11-14	2016-08-19	The Johns Hopkins University	治療精神分裂症的方法和組合物
GB201310782D0 (en)	2013-06-17	2013-07-31	Max Planck Innovation Gmbh	Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
KR102079844B1 (ko) *	2016-09-20	2020-02-20	가톨릭대학교 산학협력단	담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
US20210361664A1 (en)	2017-08-14	2021-11-25	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
CA3188730A1 (en)	2020-08-12	2022-02-17	Christopher Barnes	Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999038868A1 (en) *	1998-01-28	1999-08-05	Du Pont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6191131B1 (en) *	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW444018B (en)	1992-12-17	2001-07-01	Pfizer	Pyrazolopyrimidines
WO1995010506A1 (en)	1993-10-12	1995-04-20	The Du Pont Merck Pharmaceutical Company	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
WO1997035846A1 (en)	1996-03-26	1997-10-02	Dupont Pharmaceuticals Company	Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
US6107300A (en)	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
AU3064397A (en)	1996-05-24	1997-12-09	Dow Chemical Company, The	Process for preparing aliphatic ester compounds and alkanols
CZ299451B6 (cs) *	1996-07-24	2008-07-30	Bristol-Myers Squibb Pharma Company	[1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi
DK0915880T3 (da)	1996-07-24	2008-02-11	Bristol Myers Squibb Pharma Co	Azolotriaziner og pyrimidiner
TR199900389T2 (xx) *	1996-08-28	2000-06-21	Pfizer Inc.	�kame edilmi� 6,5-hetero-bisiklik t�revleri.
UA62972C2 (en)	1997-07-03	2004-01-15		Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
SK179899A3 (en)	1997-07-03	2001-12-03	Du Pont Pharm Co	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
JP2002510322A (ja)	1997-07-03	2002-04-02	デュポンファーマシューティカルズカンパニー	副腎皮質刺激ホルモン放出ホルモン拮抗剤としてのアリールおよびアリールアミノ置換複素環
JP2001514260A (ja)	1997-09-02	2001-09-11	デュポンファーマシューティカルズカンパニー	Ｃｎｓおよびストレス関連疾患の治療に有用な、副腎皮質刺激ホルモン放出ホルモン拮抗剤としての、複素環基が置換した環縮合ピリジン類およびピリミジン類
US6194410B1 (en)	1998-03-11	2001-02-27	Hoffman-La Roche Inc.	Pyrazolopyrimidine and pyrazolines and process for preparation thereof
WO1999051608A1 (en)	1998-04-03	1999-10-14	Du Pont Pharmaceuticals Company	THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
US6124463A (en)	1998-07-02	2000-09-26	Dupont Pharmaceuticals	Benzimidazoles as corticotropin release factor antagonists
EP1183033B1 (en) *	1999-05-21	2006-03-01	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
CA2440553C (en) *	2001-03-13	2010-06-08	Paul J. Gilligan	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

2002
- 2002-03-06 CA CA2440553A patent/CA2440553C/en not_active Expired - Fee Related
- 2002-03-06 CN CNB028064151A patent/CN100427093C/zh not_active Expired - Fee Related
- 2002-03-06 ES ES02713776T patent/ES2282401T3/es not_active Expired - Lifetime
- 2002-03-06 SK SK1157-2003A patent/SK287603B6/sk not_active IP Right Cessation
- 2002-03-06 EP EP02713776A patent/EP1368094B1/en not_active Expired - Lifetime
- 2002-03-06 GE GE5322A patent/GEP20053608B/en unknown
- 2002-03-06 DE DE60218434T patent/DE60218434T2/de not_active Expired - Lifetime
- 2002-03-06 PL PL368644A patent/PL208278B1/pl unknown
- 2002-03-06 HR HR20030822A patent/HRP20030822B1/xx not_active IP Right Cessation
- 2002-03-06 HU HU0303480A patent/HU229317B1/hu not_active IP Right Cessation
- 2002-03-06 AT AT02713776T patent/ATE355102T1/de active
- 2002-03-06 EE EEP200300435A patent/EE05433B1/xx not_active IP Right Cessation
- 2002-03-06 WO PCT/US2002/006837 patent/WO2002072202A1/en not_active Ceased
- 2002-03-06 PT PT02713776T patent/PT1368094E/pt unknown
- 2002-03-06 US US10/092,312 patent/US20030125330A1/en not_active Abandoned
- 2002-03-06 RS YUP-715/03A patent/RS50863B/sr unknown
- 2002-03-06 DK DK02713776T patent/DK1368094T3/da active
- 2002-03-06 NZ NZ528207A patent/NZ528207A/en not_active IP Right Cessation
- 2002-03-06 AU AU2002245605A patent/AU2002245605B2/en not_active Ceased
- 2002-03-06 RU RU2003130093/04A patent/RU2292347C2/ru not_active IP Right Cessation
- 2002-03-06 MX MXPA03008185A patent/MXPA03008185A/es active IP Right Grant
- 2002-03-06 JP JP2002571157A patent/JP4549630B2/ja not_active Expired - Fee Related
- 2002-03-06 KR KR1020037011913A patent/KR100875595B1/ko not_active Expired - Fee Related
- 2002-03-06 IL IL15761502A patent/IL157615A0/xx unknown
- 2002-03-06 CZ CZ20032481A patent/CZ20032481A3/cs unknown
- 2002-03-06 BR BR0208357-4A patent/BR0208357A/pt active Search and Examination
- 2002-03-12 MY MYPI20020879A patent/MY146935A/en unknown
- 2002-03-13 TW TW091104706A patent/TWI257388B/zh not_active IP Right Cessation
- 2002-03-13 AR ARP020100908A patent/AR032986A1/es not_active Application Discontinuation
- 2002-06-03 UA UA2003109244A patent/UA74634C2/uk unknown
2003
- 2003-02-05 US US10/358,652 patent/US7157578B2/en not_active Expired - Lifetime
- 2003-08-27 IL IL157615A patent/IL157615A/en not_active IP Right Cessation
- 2003-09-08 ZA ZA200306995A patent/ZA200306995B/en unknown
- 2003-09-10 IS IS6947A patent/IS2839B/is unknown
- 2003-09-11 NO NO20034023A patent/NO328580B1/no not_active IP Right Cessation
- 2003-09-23 BG BG108189A patent/BG66331B1/bg unknown
2006
- 2006-11-07 US US11/593,715 patent/US7358252B2/en not_active Expired - Lifetime
2007
- 2007-05-18 CY CY20071100678T patent/CY1106607T1/el unknown
2008
- 2008-02-13 US US12/030,439 patent/US7662817B2/en not_active Expired - Lifetime

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6191131B1 (en) *	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
WO1999038868A1 (en) *	1998-01-28	1999-08-05	Du Pont Pharmaceuticals Company	Azolo triazines and pyrimidines

Also Published As

Publication number	Publication date
DE60218434T2 (de)	2007-11-08
NO328580B1 (no)	2010-03-22
JP4549630B2 (ja)	2010-09-22
ES2282401T3 (es)	2007-10-16
US7358252B2 (en)	2008-04-15
WO2002072202A1 (en)	2002-09-19
CA2440553A1 (en)	2002-09-19
BG66331B1 (bg)	2013-06-28
CN1509196A (zh)	2004-06-30
BR0208357A (pt)	2004-06-29
CA2440553C (en)	2010-06-08
US7157578B2 (en)	2007-01-02
HK1057182A1 (en)	2004-03-19
KR100875595B1 (ko)	2008-12-23
IL157615A (en)	2009-09-01
SK287603B6 (sk)	2011-03-04
US20080139567A1 (en)	2008-06-12
YU71503A (sh)	2006-05-25
HU229317B1 (en)	2013-10-28
HUP0303480A3 (en)	2005-12-28
HRP20030822A2 (en)	2004-04-30
NO20034023L (no)	2003-09-11
RS50863B (sr)	2010-08-31
DK1368094T3 (da)	2007-07-02
EP1368094A1 (en)	2003-12-10
US20040014760A1 (en)	2004-01-22
MXPA03008185A (es)	2004-01-29
MY146935A (en)	2012-10-15
ATE355102T1 (de)	2006-03-15
AU2002245605B2 (en)	2006-02-02
DE60218434D1 (en)	2007-04-12
BG108189A (bg)	2004-09-30
TWI257388B (en)	2006-07-01
UA74634C2 (uk)	2006-01-16
US20070054913A1 (en)	2007-03-08
JP2004530662A (ja)	2004-10-07
IL157615A0 (en)	2004-03-28
IS6947A (is)	2003-09-10
IS2839B (is)	2013-06-15
NO20034023D0 (no)	2003-09-11
RU2292347C2 (ru)	2007-01-27
US7662817B2 (en)	2010-02-16
CY1106607T1 (el)	2012-01-25
NZ528207A (en)	2006-02-24
RU2003130093A (ru)	2005-03-20
PL368644A1 (en)	2005-04-04
US20030125330A1 (en)	2003-07-03
KR20030080086A (ko)	2003-10-10
HUP0303480A2 (hu)	2004-01-28
PT1368094E (pt)	2007-05-31
GEP20053608B (en)	2005-09-12
ZA200306995B (en)	2004-09-08
CN100427093C (zh)	2008-10-22
EE05433B1 (et)	2011-06-15
SK11572003A3 (sk)	2004-02-03
AR032986A1 (es)	2003-12-03
EE200300435A (et)	2003-12-15
EP1368094B1 (en)	2007-02-28
PL208278B1 (pl)	2011-04-29
CZ20032481A3 (cs)	2007-12-27
EP1368094A4 (en)	2004-03-31

Publication	Publication Date	Title
HRP20030822B1 (en)	2008-01-31	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
YU27697A (sh)	2000-03-21	Sulfonamidi i njihiova upotreba
HUP9901820A2 (hu)	1999-09-28	4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
PT970084E (pt)	2003-10-31	Pirrolo¬2,3d\|pirimidinas e sua utilizacao como inibidores da tirosina-cinase
WO2001019829A3 (en)	2001-09-27	Pyrazolopyrimidines as therapeutic agents
AR030507A1 (es)	2003-08-20	Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
TR200201638T2 (tr)	2002-11-21	Yeni imidazo[1,3,5]triazinonlar ve kullanımları
ES2421948T3 (es)	2013-09-06	Compuestos y composiciones para suministrar agentes activos
IS5352A (is)	2000-01-19	Ný efnasambönd
SE9703375D0 (sv)	1997-09-18	A new combination
EA199900161A1 (ru)	1999-10-28	Производные пиридазино [4,5-в]-хинолин-5-оксида, их получение и применение в качестве антагонистов глицина
FI951300A0 (fi)	1995-03-20	Alfutsosiinihydrokloridin hitaan vapautumisen galeenisia muotoja
AR029343A1 (es)	2003-06-25	USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
BR0110357A (pt)	2004-04-20	Sais bicìclicos e n-aciclados de aminas imidazo - 3 e imidazo -5
SE9702563D0 (sv)	1997-07-02	Compounds
BR0109784A (pt)	2003-01-21	Uracilas de fenila substituìdas
CO4990949A1 (es)	2000-12-26	Derivados de imidazol y su preparacion .
NO306781B1 (no)	1999-12-20	Imidazo[1,2-a]kinoksalinforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter
PL353681A1 (en)	2002-11-04	Applications of pyrrole derivatives in production of a drug
DE502004007387D1 (de)	2008-07-31	Triazolverbindungen und ihre therapeutische verwendung
DE69910574D1 (de)	2003-09-25	Pyrazolo[1,5-a]triazine als crf antagonisten
HRP20090190T1 (en)	2009-05-31	Pharmaceutical composition comprising a salt of mirtazapine
ES2144888T3 (es)	2000-06-16	4-(6-fluoro-(1h)-indol-3-il)-1,2,3,6-tetrahidropiridina sustituida para el tratamiento de desordenes del snc.
FR2823752A1 (fr)	2002-10-25	Nouveaux derives de pyrimidin-4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE318268T1 (de)	2006-03-15	Pyrazolyl-substituierte triazolochinoxaline

Legal Events

Date	Code	Title	Description
2004-04-30	A1OB	Publication of a patent application
2004-10-19	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2008-01-31	B1PR	Patent granted
2016-02-02	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20160202 Year of fee payment: 15
2017-09-26	PBON	Lapse due to non-payment of renewal fee	Effective date: 20170306